Form 4: Cidara Therapeutics COO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Shane Ward, COO & CLO of Cidara Therapeutics, sold shares to cover tax withholding obligations related to the vesting and settlement of RSUs.
Summary
- On March 11, 2024, Shane Ward, the COO & CLO of Cidara Therapeutics, sold 20,473 shares of common stock at a weighted average price of $0.6698.
- The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
- Following the transaction, Ward directly owns 198,770 shares of Cidara Therapeutics.
- This includes 8,000 shares acquired through the company's Employee Stock Purchase Plan (ESPP) on May 19, 2023, and November 20, 2023.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (sale of shares for tax obligations) and doesn't inherently indicate positive or negative sentiment regarding the company's prospects.
Industry Context
Form 4 filings are a routine part of insider trading activity and are required by the SEC to provide transparency into the transactions of company executives and directors.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of stock sale transaction |
| 03/12/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.